|Articles|January 1, 2008 (Updated: November 15, 2020)

static page images

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

FDA Approves Johnson & Johnson’s Tecvayli as Second Line Treatment for RRMM

ByMike Hollan

March 6th 2026

uniQure and FDA Clash Over Regulatory Decision for Huntington’s Disease Therapy: Report

ByNicholas Jacobus

March 6th 2026

George Kridner, President and CEO of Acelpa Health

From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma

ByGeorge Kridner

March 6th 2026

Advancing Full-Spectrum Cannabis Through FDA

ByMike Hollan,Joel Stanley

March 6th 2026

Consent‑Driven Targeting: Building Trust With Patients and HCPs

ByKevin King

March 5th 2026

static page images

Newsletter

Related Content

FDA Approves Johnson & Johnson’s Tecvayli as Second Line Treatment for RRMM

uniQure and FDA Clash Over Regulatory Decision for Huntington’s Disease Therapy: Report

From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma

Advancing Full-Spectrum Cannabis Through FDA

Consent‑Driven Targeting: Building Trust With Patients and HCPs

Trending on PharmExec

uniQure and FDA Clash Over Regulatory Decision for Huntington’s Disease Therapy: Report

Advancing Full-Spectrum Cannabis Through FDA

From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma

Eli Lilly Launches Employer Connect Platform Offering Obesity Coverage Options

Three Imperatives Pharma Leaders Should Prioritize This Year